UNSPSC 51371807: Trimeperidine hydrochloride

This classification denotes an opioid receptor agonist C17H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3696V8BXT, chemically known as propionic acid, 1,2,5-trimethyl-4-phenyl-4-piperidyl ester, hydrochloride, but more generally known as trimeperidine hydrochloride, which bears US NIH Compound Identifier 98519. European Medicines Agency schedules Trimeperidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04968MIG.

Most nations, for tariff and trade purposes, schedule trimeperidine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, TRIMEPERIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC(=O)O[C@]1(C[C@@H](N(C[C@H]1C)C)C)C2CCCCC2.CL.

UNSPSC 51371807 Trimeperidine hydrochloride is a Commodity code that encompasses pharmaceutical active ingredients and finished pharmaceutical products procured by state and local health agencies, primarily through centralized cooperative purchasing agreements and competitive bidding. State and local governments acquire these products to support community health initiatives, pharmacy benefit programs, and emergency response systems. Recent solicitations show demand spanning naloxone and drug deactivation systems for public health departments, generic multi-source pharmaceuticals through state purchasing cooperatives, and direct-to-manufacturer prescription programs designed to improve fulfillment efficiency and cost management within state pharmacy benefit systems.

Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The geographic spread covers Florida, Texas, Minnesota, and Oregon based on recent activity. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor capabilities for a direct-to-manufacturer prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. MMCAP's solicitation requires vendor compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintenance of relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., and comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence.